INOVIO Announces Publication of Phase 1 Data from its COVID-19...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
PLYMOUTH MEETING, Pa., Dec. 24, 2020 /PRNewswire-AsiaNet/ -- -- Peer-reviewed Phase 1 data shows INO-4800 to be immunogenic in 100% of subjects, inducing neutralizing antibody and/or T cell responses-- INO-4800 demonstrates favorable safety and tolerability, with no serious adverse events reported--...
Authors: LATEST ASIANET NEWS RELEASES